Physician profile
Sheila Sanchez
NPI 1164605523
$1,443.29
in general payments reported to CMS, 2019-2025
17 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.60 · 2021: $42.39 · 2022: $67.08 · 2023: $1,039 · 2024: $84.45 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759 · Travel and Lodging: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.25 |
| Travel and Lodging | $519.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $936.01 | 2023 | |
| Boston Scientific Corporation | $155.76 | 2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $69.90 | 2022-2023 | Trelegy Ellipta |
| Sanofi Pasteur INC. | $47.85 | 2023-2024 | |
| Medtronic, INC. | $41.83 | 2024 | Intellis Adaptivestim |
| Abbott Laboratories | $31.16 | 2023 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.68 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.02 | 2019 | |
| Novo Nordisk INC | $23.39 | 2023 | Rybelsus, Ozempic |
| Sunovion Pharmaceuticals INC. | $20.26 | 2022 | |
| Merck Sharp & Dohme LLC | $20.14 | 2024 | Vaxelis, Gardasil, Vaqta |
| Genentech USA, INC. | $13.71 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.